

TUMOR XENOGRRAFT MODELS

Tumor modeling in-vivo is an acceptable platform for the study of cancer growth and metastasis, characterized by inoculation of cancer cells in immunosuppressed murines. The two most used models for the assessment of potential efficacy of tested technology are the xenograft and the orthotopic models. In combination with in-vitro systems, such as angiogenesis, the prediction of response can be fully evaluated.

Pharmaseed provides a comprehensive array of translational research and development services, from early-stage R&D to first-in-man. Our state-of-the-art GLP-accredited laboratories and animal facility are well equipped to address the needs of all developmental stages of pharmaceutical, medical device and biotechnology products.

With more than 200 years of accumulated experience in basic and applied scientific research, Pharmaseed is your preferred choice of R&D partner.

EXPERIMENTAL MOUSE MODELS OUTCOME MEASURES

- | | |
|---|---|
| <ul style="list-style-type: none"> • ATHYMIC NUDE • SCID • CD-1 • CB6F1 | <ul style="list-style-type: none"> • ANGIOGENESIS BY LDF • METASTATIC GROWTH • TUMOR WEIGHT AND VOLUME • SURVIVAL |
|---|---|

TUMOR XENOGRRAFTS

- BREAST
- COLON
- MELANOMA
- OVARIAN
- PANCREAS
- PROSTATE
- BRAIN
- BONE
- BLADDER
- CERVIX
- SKIN
- LIVER
- LEUKAEMIA/ LYMPHOMA
- NEURONAL

MORPHOLOGICAL EVALUATION

- H&E STAINING (NECROSIS OR PRESENCE OF NON-TUMOUR MASS, MITOTIC INDEX AND INFLAMMATION INDICES)
- FACTOR VIII ENDOTHELIAL CELL STAINING (TUMOR'S BLOOD PERFUSION)

CONTACT

Tomer Shemesh, PhD
Business Development Unit

9 Hamazmera St.
Ness Ziona 74047
Israel

Phone: +972-8-9302771 ext. 107
Fax: +972-8-9302773
E-mail: tomer@pharmaseedltd.com




Figure: Changes in *in-vivo* tumor growth (HTC 116) following treatment with low or high doses of doxorubicin.

